RBR-9hckj4
Completed
Phase 1
Phase I trial to evaluate safety and immunogenicity of Measles and Rubella vaccine (MR) for measles and rubella, in young adults
Bio-Manguinhos/Fiocruz/MS0 sitesSeptember 12, 2016
ConditionsMeasles and Rubella
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Measles and Rubella
- Sponsor
- Bio-Manguinhos/Fiocruz/MS
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy volunteers on screening; male; aged between 18\-49 years; availability to provide personal data; availability in strictly follow the research protocol; accept not participate in any other clinical trial during this one and up to 6 months after the end; ability to understand and sign the informed consent term; ability to record symptoms at home; acceptance of HIV testing for HIV, HBV and HCV.
Exclusion Criteria
- •Serious adverse event due to the study vaccination; acute or chronic disease; use of allergy shots with antigens, up to 14 days prior to study vaccination; immunoglobulin use in the last 12 months prior to vaccination; use of blood products in the 12 months prior to vaccination; use of any type of vaccine 30 days before vaccination; Chronic use of any medication, except for homeopathic and trivial; previous use of immunosuppressant or cytotoxic medication; use of any investigational medication 1 year prior to vaccination; asthma (unstable, that has required urgent care in the last 24 months, or requiring the use of corticosteroids); neurological, cardiovascular, respiratory, hepatic, renal, hematologic, rheumatic or autoimmune \- clinically significant; coagulopathies; Seizures before age 2 years; psychiatric illness that hinder adherence to the protocol; Active malignancy; asplenia; HIV, HCV and / or HBV positive; alcohol abuse (CAGE criteria); illicit drugs abuse; congenital or acquired immunodeficiency; allergy vaccine components, such as egg, neomycin and gelatin.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A Phase I trial to assess safety and immunogenicity of i.d. DNA priming and i.m. MVA boosting in healthy volunteers in MozambiqueHIV/AIDSPACTR201106000304583Swedish Institute for Infectious Disease Control24
Recruiting
Phase 1
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9Influenza prophylaxisTherapeutic area: Diseases [C] - Virus Diseases [C02]CTIS2022-500706-18-01Oslo University Hospital Hf30
Completed
Not Applicable
Phase I clinical trial to assess safety and immunogenicity of an MVA-based influenza H5 vaccine in healthy adultsfluInfluenza10047438NL-OMON38408Erasmus MC, Universitair Medisch Centrum Rotterdam27
Unknown
Phase 2
HIVIS03PACTR2009040001075080Swedish Institute for Infectious Disease Control (SMI)
Active, not recruiting
Not Applicable
Phase I and IIa trial to assess the safety, immunogenicity and protective efficacy against sporozoite challenge of the candidate malaria vaccine pfLSA-3 vaccine. - LSA3-trialP. falciparum infection (malaria)EUCTR2006-001743-66-NLINSTITUT PASTEUR, Biomedical Parasitology Unit